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Abstract
Aims—DNA methylation is increasingly proposed as a mechanism for underlying asthma-related
inflammation. However, epigenetic studies are constrained by uncertainties on whether samples
that can be easily collected in human individuals can provide informative results.
Methods—Two nasal cell DNA samples were collected on different days by nasal brushings
from 35 asthmatic children aged between 8 and 11 years old. We correlated DNA methylation of
IL-6, iNOS, Alu and LINE-1 with fractional exhaled nitric oxide, forced expiratory volume in 1 s
and wheezing.
Results—Fractional exhaled nitric oxide increased in association with lower promoter
methylation of both IL-6 (+29.0%; p = 0.004) and iNOS (+41.0%; p = 0.002). Lower IL-6
methylation was nonsignificantly associated with wheezing during the week of the study (odds
ratio = 2.3; p = 0.063).
Conclusion—Our findings support the use of nasal cell DNA for human epigenetic studies of
asthma.
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Asthma is the most common chronic disease of childhood in developed countries, affecting
nearly 6.5 million children in the USA [1], and 234.9 million individuals worldwide [2].
Airway inflammation is a key feature in the pathogenesis of childhood asthma [3], and is
characterized by the presence of inflammatory cells and release of inflammatory mediators
in the airways [4]. Growing evidence shows that expression and responsiveness of several
inflammatory mediators are programmed through epigenetic mechanisms, such as DNA
methylation [5–7]. In humans, DNA methylation contributes to silencing gene expression
through the addition of methyl groups to cytosine to form 5-methyl-cytosine (5mC) [8].
DNA methylation is largely established in utero or during early life, but also shows changes
thereafter in response to environmental stressors [9–12].
As a feature of the asthma-associated eosinophilic inflammation, asthma patients exhibit an
increase in nitric oxide (NO) production [4], predominantly due to overexpression in the
airway epithelium of the inducible nitric oxide synthase (iNOS) [13]. Studies of iNOS
activation have shown that lower DNA methylation in the gene promoter is associated with
increased expression [7]. Among inflammatory mediators that are relevant to asthma,
consistent evidence has shown that IL-6 expression is associated with reduced DNA
methylation of its gene promoter [5,6]. IL-6 is central to inflammatory processes underlying
chronic inflammatory diseases, including allergic asthma, and have been shown to induce
the expression of other genes that might contribute to the asthma phenotype [14].
Although inflammation-related processes have been associated with changes in DNA
methylation of promoters in specific genes, including IL-6 and iNOS, the bulk of DNA
methylation in the human genome is located in intergenic DNA [15,16]. In particular, Alu
and long interspersed nucleotide element 1 (LINE-1) repetitive elements, which are
sequences of intergenic DNA repeated in up to 1 million copies per haploid genome,
represent approximately 30% of the human genome and are heavily methylated [17]. Alu
and LINE-1 methylation have been shown to correlate with the global amount of DNA
methylation in the genome based on studies with cancer tissues [15,16], has been shown to
decrease in response to inflammation and oxidative stress [18–20].
DNA methylation patterns are tissue specific, and one critical limitation for human
epigenetic studies is that tissues that are relevant for disease etiology cannot be easily
obtained in most cases from patients and study participants [21]. Human in vivo studies of
DNA methylation have often used blood [10,20,22–28] or buccal cells [11,29,30] as easily
obtainable biospecimens in patients as well as in healthy individuals. Nasal epithelial cells
have been proposed as surrogates for bronchial epithelial cells in airway inflammation
studies [31]. However, to the best of our knowledge, nasal cell DNA methylation has never
been evaluated in relation to asthma. In the present work, we sought proof-of-principle as to
whether the levels of methylation of the IL-6 and iNOS gene promoters, and of Alu and
LINE-1 repetitive elements – measured in nasal cells – were correlated with fractional
exhaled nitric oxide (FENO), forced expiratory volume in 1 second (FEV1), and wheezing in
a small panel study of children with current asthma.
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Materials & methods
Study subjects
Between December 2007 and April 2008, we performed a panel study in children with
asthma, identified during a cross-sectional investigation conducted in the area of Milazzo-
Valle del Mela (Sicily, Italy). The cross-sectional screening was originally prompted by
concerns due to the presence of a major petrochemical plant and an oil-powered thermal
plant in the area and was conducted on all the 2506 resident children (8–11 years old)
attending the local primary schools (response rate: 89.5%), in order to provide data on their
respiratory health.
We used the International Study of Asthma and Allergy in Childhood (ISAAC) core
questionnaire [32], to ascertain lifetime and past year prevalence of asthma and wheezing,
and added questions about child’s respiratory health and risk factors for asthma derived from
the Italian Studies on Respiratory Diseases in Childhood and the Environment (SIDRIA)
Phase II study [33], the Italian section of ISAAC. Questionnaires were completed at home
by the parents. For the panel study, we selected all the children who: had a physician
diagnosis of asthma; reported wheezing symptoms in the previous 12 months; and had chest
tightness and/or use of bronchodilators in the last 12 months (n = 50).
Written informed consent to participate in the panel study was obtained from the parents of
35 of the 50 children, and therefore comprised our study population of 35 participants. The
reason for refusal was the concern for the invasiveness of the nasal brushing procedure. The
children who did not participate in the study were not different in asthma severity from those
who participated (data not shown). Each child was followed-up for 7 consecutive days. A
diary on daily respiratory symptoms (e.g., symptoms of cold to rule out acute respiratory
infections; wheezing symptoms and chest tightness); and on bronchodilators, inhaled
steroids and antileukotrienes use, was completed by the parents of study subjects. The
protocol of the study was approved by the Ethics Committee of the University of Cagliari,
Italy.
Nasal mucosa cell collection & DNA extraction from nasal cell pellets
In the afternoon (4–6 pm) on days 4 and 7 (Tuesday and Friday) of the study, each child
went to a dedicated out-patient clinic to undergo nasal brushing to collect nasal cells for
DNA methylation analysis. Nasal brushing was performed on day 4 in the right nostril and
on day 7 in the left nostril by a trained nurse, following standardized procedures. Each of the
children was first asked to blow his/her nose into nonscented tissue paper to clear any mucus
discharge. In case of mucus the nurse washed the nasal cavity with 2–4 ml saline solution
(0.9% NaCl) inserted via a syringe (with no needle inserted) and cleaned it with a cotton
swab. Nasal cells were collected by soft brushing of the inferior turbinate with a cytobrush
Plus® (CooperSurgical, CT, USA). Nasal cells were gently rinsed from the cytobrush into a
tube containing 6 ml of saline solution (0.9% NaCl) and 10% acetylcysteine (200 mg/ml)
and then incubated for 30 min at room temperature (100 cycles/min shaking frequency).
After centrifugation, the cell pellets were kept at −20°C until shipment from the study site to
the central laboratory. All specimens were blind coded. DNA was extracted with the
Maxwell Automatic Extractor® (Promega, Madison, WI, USA) using tissue cartridges and
eluted in a 300-μl final volume.
DNA methylation analyses by bisulfite pyrosequencing
We used quantitative analysis by means of PCR-pyrosequencing on bisulfite-treated DNA to
measure DNA methylation in the promoter regions of IL-6 and iNOS, as well as in Alu and
LINE-1 repetitive elements [10,25]. EZ DNA Methylation-Gold Kit (Zymo Research,
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Orange, CA, USA) was used to treat 0.5 μg DNA (concentration 50 ng/μl), according to the
manufacturer’s protocol. Final elution was performed with 30 μl M-elution buffer. The
within-sample coefficients of variation between the pyrosequencing duplicates for these
markers were 0.7% for LINE-1, 1.6% for Alu, 0.7% for iNOS and 4.0% for IL-6. Primers
and conditions for each of the assays are reported in Table 1. Methods and primers for
measuring iNOS promoter DNA methylation, as well as analyses of Alu and LINE-1
methylation that allow for the amplification of a representative pool of repetitive elements,
were recently described [10]. We developed a new assay for IL-6 promoter methylation, by
locating the IL-6 promoter using the Genomatix Software (Genomatix Software Inc., Ann
Arbor, MI, USA) on chromosome 7 (start = 22732791, end = 22733685), and amplified the
sequence between 22733756 and 22733893. A 50-μL PCR was carried out in 25 μl GoTaq®
Green Master mix (Promega), 10 pmol forward primer, 10 pmol reverse primer, 50 ng
bisulfite-treated genomic DNA and water. PCR cycling conditions were 95°C for 60 s, 57°C
for 60 s and 72°C for 60 s for 45 cycles. PCR products were purified and sequenced by
pyrosequencing as previously described using a 0.3-μM sequencing primer [25].
For all assays we used built-in controls to verify bisulfite conversion efficiency. Compared
with other common methods of DNA methylation analysis, pyrosequencing-based assays
have the advantage of producing individual measures of methylation at more than one CpG
dinucleotide, thus reflecting more accurately DNA methylation in the region [34,35]. In the
Alu or LINE-1 assays, we measured the percentage of 5mC (%5mC) at each of three CpG
dinucleotide positions that are repeated over the human genome with the sequence of
interest. In the iNOS promoter assay, we measured %5mC at each of two individual CpG
dinucleotides within a CpG island located in the gene promoter. In the IL-6 promoter assay,
we measured %5mC at two individual CpG dinucleotides within a CpG island located
downstream in the proximity of the gene promoter. %5mC levels of individual CpG
dinucleotides were averaged to obtain a mean measure for each of the assays. The basis for
using the average was the observation that methylation values in adjacent CpG sites over a
short amplicon such as that used in pyrosequencing analysis are usually highly correlated
[36]. In our previous work, we observed that averages of DNA methylation within each
amplicon provide more robust methylation measures compared with analyses of individual
CpGs [37]. Every sample was tested twice for each assay to confirm reproducibility, and the
average of the two measurements was used in the statistical analysis.
FENO & FEV1 measurements & wheezing symptoms
FENO and FEV1 measurements were performed during the same visits when nasal cell DNA
was collected. The children were trained by a nurse on the day before the beginning of the 7-
day follow-up, and collection of exhaled air for FENO measurement and the forced
expiratory maneuver were supervised by the same nurse during the study week. Ambient
NO and FENO concentrations were assessed by chemiluminescence using the NIOX
analyzer (Aerocrine, Stockholm, Sweden) and following the American Thoracic Society/
European Respiratory Society recommended procedures (American Thoracic Society/
European Respiratory Society) [38]. FEV1 was recorded using the PiKo®1 electronic FEV1
meter (Ferraris Respiratory Europe, Hereford, UK), a monitoring device that uses a patented
pressure/flow sensor technology, and which has been demonstrated to be accurate at
measuring the FEV1 in similar conditions [39]. The occurrence of wheezing (during the day,
night or exercise) was recorded by the daily diary.
Statistical methods
Means and standard deviations (SDs) were used to summarize the data. In our study, each
child participated in two visits in which FEV1, FENO and methylation data were collected.
Therefore, our data may lack independence. To evaluate the association of DNA
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methylation with FEV1 or FENO, we fitted generalized estimating equation (GEE)
population averaged models. GEE were fitted by specifying a generalized linear model
(GLM) extension to each of the visits at which FENO, FEV1, and DNA methylation were
measured. We used the GEE extension of GLM. We specified a γ family for the continuous
responses (FEV1 or FENO), because both FEV1 and FENO exhibited slightly asymmetrical
distributions with constant coefficients of variation [40]. We used a log-link, which also
allows reporting the results as easily interpretable percentage variation for unit increase in
the predictor. These choices are common in GEE implementation and supported in standard
textbooks [40,41]. We specified an independent working correlation, which is robust in the
presence of noisy data, and used the Huber–White estimator of standard errors [40]. The
adoption of the Huber–White estimator ensures that standard errors are unbiased even if the
correlation structure is misspecified.
DNA methylation, FENO and FEV1 data were used as continuous variables and results were
expressed as percent variation (%v) of FENO or FEV1 in relation to interquartile-range
(IQR) changes in DNA methylation (i.e., IL-6: IQR = 16.1 %5mC; IQR = iNOS: 9.4 %5mC;
Alu: IQR = 0.9 %5mC; LINE: IQR = 4.9 %5mC). We fitted GEE regression models in
which all four DNA methylation markers (i.e., iNOS, IL-6, Alu and LINE-1) were included
as independent explanatory variables. We also determined the association of DNA
methylation with wheezing symptoms (yes/no, evaluated on the day of nasal brushing) by
fitting a multivariable GEE regression model for binary data (i.e., binomial family with logit
link). Again, we specified an independent working correlation and used the Huber–White
estimator of standard errors [40].
All observations with FENO levels below the detection limit of 5 parts per billion (five
measurements) were excluded from the analysis. In addition, to avoid interference from
ambient NO on the FENO readings, we excluded readings (two measurements) taken when
ambient NO was >5 parts per billion. One additional observation was excluded due to
missing FEV1 data. Therefore, out of the total 70 observations (35 subjects × two
measurements), we conducted statistical analyses on 62 observations without missing data
for any of the variables mentioned above.
Because the main purpose of the present observational study was to explore associations
between DNA methylation and respiratory outcomes, we interpreted our data, based on the
strength of the associations, as often done in observational studies [42], within the context of
the available evidence on biological functions [43]. Accordingly, we reported confidence
intervals using 90% levels, as indicated in the Sterne and Davey-Smith’s suggested
guidelines for the reporting of results of statistical analyses in medical journals [43].
However, to conform to standard practice in biological reports, in the text we indicated
findings with two-sided p < 0.05 as statistically significant. The study protocol included
power calculations on the primary out-come (FEV1). We used the formula for panel studies
reported in [40]. The sample size required ranged between 30 and 60 for within-subject
correlation from 0.5–0.0, power 80% α = 0.05 two-sided. All the statistical analyses were
performed using Stata 11 (Stata Corporation, College Station, TX, USA).
Results
Study population
The panel study consisted of 35 Caucasian children, 27 males and 8 females whose
characteristics are reported in Table 2.
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DNA methylation & its relationship with FENO, FEV1 & wheezing
Table 3 reports descriptive statistics for FENO, FEV1 and DNA methylation of the IL-6 and
iNOS promoters, as well as of Alu and LINE-1 repetitive elements. The correlation matrix of
IL-6, iNOS, Alu and LINE-1 methylation showed significant correlations among the
methylation markers (Figure 1). Consequently, we fitted multivariable GEE regression
models to estimate the net association of each methylation markers (IL-6, iNOS, Alu or
LINE-1) with FENO or FEV1 taking into account the methylation levels of the other
methylation markers. In these models (Table 4), FENO was negatively associated with both
IL-6 (−29.0 %v per interquartile change in IL-6 methylation; 90% CI: −44.0 to −12.9 %v; p
= 0.004) and iNOS methylation (−41.0 %v per interquartile change in iNOS methylation;
90% CI: −61.6 to −20.4 %v; p = 0.002). FEV1 was not associated with IL-6 (5.6 %v per
interquartile change in IL-6 methylation, 90% CI: −1.5–12.7 %v; p = 0.20) and iNOS
methylation (0.05 %v per interquartile change in iNOS methylation, 90% CI: −3.5–3.6 %v;
p = 0.98). Alu and LINE-1 methylation showed no associations with FENO and FEV1 (Table
4). When we evaluated the DNA methylation markers in relation to wheezing (yes/no)
during the week of the study, we found a moderate nonsignificant association with lower
methylation of the IL-6 promoter (odds ratio = 2.3 for wheezing; 90% CI: 1.1–4.9; p = 0.063
per interquartile decrease in IL-6 methylation).
We also explored whether DNA methylation was affected by exposure to environmental
tobacco smoke (ETS), using information on maternal smoking as proxy of exposure. Neither
current nor past maternal smoking was associated with IL-6 methylation (p = 0.64, and p =
0.73 respectively in analysis adjusted for child age and gender) or iNOS methylation (p =
0.19 and p = 0.49, respectively, in analysis adjusted for child age and gender). Most of the
children included in our study were boys (n = 27). We performed a separate set of analyses
on boys only, which did not show relevant differences from the analyses conducted on all
children. For instance, the age- and gender-adjusted associations of IL-6 and iNOS
methylation with FENO in boys only were −28.4 %v per interquartile change in IL-6
methylation (90% CI: −43.2 to −13.6 %v; p = 0.002) and −38.5 %v per interquartile change
iNOS methylation (90% CI: −56.4 to −20.6 %v; p = 0.001).
Sensitivity analyses
All models reported above were adjusted for age (as a continuous variable) and gender.
Because FEV1 is highly dependent on height, all modelsused to evaluate FEV1 were also
adjusted by height (as a continuous variable). In sensitivity statistical analyses, we fitted
multivariable models that also included as independent variables subject’s height and
weight, parental education, ETS exposure, mould or damp in the childs room, symptoms of
rhino-conjunctivitis (as a proxy of atopy), traffic intensity in the street of residence (as
measured in [44]), recent respiratory infections, use of inhaled steroid for asthma, day of the
week, outdoor temperature and relative humidity. The regression coefficients expressing the
associations of the DNA methylation variables with the response variables in the set of
models adjusted for the potential confounders mentioned above did not show major
differences from coefficients adjusted for the smaller set of confounders (data not shown).
Discussion
Implications for human epigenetics of asthma
In this study of a small sample of asthmatic children, we found that individuals with lower
DNA methylation of the IL-6 and iNOS promoters in nasal cells had higher airway
inflammation, as measured by increased FENO. Promoter hypomethylation has been
demonstrated as a mechanism through which both iNOS [7] and IL-6 [5] are derepressed or
brought at a higher set point. The levels of FENO in patients with asthma are predominantly
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due to iNOS expression and activity in the airway epithelium [13], and vary depending on
the inflammatory status of the airways [4]. We also found that lower IL-6 promoter
methylation was associated with higher FENO, and that – as shown in multivariable
regression – this association was independent from the methylation status of the iNOS
promoter. Hypomethylation-related expression of IL-6 might therefore increase FENO by
inducing iNOS expression either through mechanisms of gene expression control alternative
to iNOS promoter demethylation or through activation at the post-transcriptional level.
Taken together, our findings indicate that demethylation of the IL-6 and iNOS promoters is a
feature of increased airway inflammation that can be detected in nasal cell DNA. Based on
our findings, we surmise that DNA methylation measured in nasal cell DNA may help
capture epigenetic modifications that extend to the lower airways. McDougall et al. have
previously reported correlations between nasal and lower airway epithelial cells in the
expression of a number of mediators, including IL-6 [31]. Also, Sridhar et al. showed strong
correlations between the nasal and bronchial epithelia in the mRNA levels of a subset of
genes from a microarray platform that were expressed in the bronchial airways of healthy
nonsmoking adult subjects [30]. However, these genes did not include those evaluated in our
study. Additional research is warranted to determine whether DNA methylation in nasal
cells collected by brushing is correlated with DNA methylation measured in other
respiratory tissues. Whereas our results suggest that nasal cell DNA analysis is informative
in the investigation of childhood asthma, and potentially of other respiratory conditions,
previous large human investigations have mostly collected buccal and/or blood DNA. The
present study was specifically focused on nasal cell DNA and did not include any collection
of buccal or blood DNA. Therefore, we are unable to evaluate whether the DNA
methylation associations that we found in nasal cell DNA can be also captured by using
other frequently collected cell types.
Although we selected IL-6 and iNOS because of the established role of DNA methylation in
programming their expression and their potential roles in relation with FENO and airways
obstruction, inflammatory states in asthma depend on a much higher number of genes across
different related pathways, and several of them would also represent strong candidates for
DNA methylation studies. For instance, mouse studies have shown that inhaled diesel
exposure and intranasal Aspergillus fumigatus allergen-induced hypermethylation at
multiple sites of the IFN-γ promoter and hypomethylation at the CpG 408 site of the IL-4
promoter [45]. Altered methylation of both gene promoters was correlated significantly with
changes in IgE levels [45]. Perera et al. recently reported that DNA methylation of the
ACSL3 gene measured in umbilical cord white blood cell DNA from a subset of children in
a cohort with high prevalence of asthma was related with polycyclic aromatic hydrocarbon
exposure and with asthma symptoms in children prior to the age of 5 years [28]. In a mouse
study, Hollingsworth et al. showed that a maternal diet rich in methyl donors was associated
with greater levels of airway hyperactivity, airway eosinophilic inflammation, and IgE
production in the F1 progeny, and partially in the F2 generation mice [46]. That same work
discovered loci differentially methylated in lung tissues after in utero supplementation with
a methyl-rich diet, including Runx3, a gene known to negatively regulate allergic airway
inflammation. Future studies are therefore warranted to expand our findings on the IL-6 and
iNOS promoters and evaluate DNA methylation of a larger number of genes.
Hypomethylation of Alu and LINE-1 repetitive elements has been previously found in
peripheral blood leukocytes in response to risk factors for asthma and respiratory disease,
such as exposure to airborne particulate matter [10,20] and pollutants from vehicular traffic
[25]. In the present study, we found that nasal cell LINE-1 methylation showed a negative
correlation with IL-6 and a positive correlation with iNOS methylation. Nonetheless, LINE-1
methylation did not show any association with FENO, FEV1 nd wheezing. The biological
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background underlying the associations of LINE-1 methylation with IL-6 and iNOS
methylation is unclear. Alu methylation showed a moderate positive correlation with
LINE-1 methylation, but not with IL-6 and iNOS methylation. Also, Alu methylation did not
show any association with FENO, FEV1 and wheezing. It is worth noting that although Alu
and LINE-1 methylation analyses have been proposed as surrogate measures of DNA
methylation based on findings on cancer tissues [15,16], no evidence is available to suggest
that Alu and LINE-1 methylation measures are associated with the global DNA methylation
content in noncancerous DNA sources. Conversely, Choi et al. did not find any correlation
between LINE-1 methylation and 5mC levels in blood leukocyte DNA from healthy
individuals [47]. In addition, most Alu and LINE-1 methylation sites are extragenic and
would therefore represent methylation levels in the vast proportion of the human genome
composed by noncoding sequences, rather than that in the smaller proportion of gene-coding
DNA [48].
Strengths & limitations
Our study was based on analysis of DNA methylation using pyrosequencing, which is
highly reproducible and accurate at quantifying DNA methylation [15,25]. Whereas other
DNA methylation techniques are only qualitative (i.e., produce a binary call of DNA
methylation as negative or positive methylation), pyrosequencing analysis is quantitative
and generates a measure of the proportion of cytosines that are methylated at a given CpG
dinucleotide position within a sequence of interest. Therefore, the measure obtained,
expressed as %5mC, reflects how many of the cells that contributed to the tested DNA were
methylated in the specific CpG dinucleotides evaluated. To that extent, data from
pyrosequencing analysis more adequately represent the control of gene expression, which
would not be appropriately captured by qualitative methods. In addition, each of the DNA
methylation assays we used in our study measured multiple individual CpG dinucleotides,
which were averaged to obtain a mean measure for each marker, and were repeated twice on
each sample to minimize the assay variability. We also designed our assays to evaluate DNA
methylation in the promoters of IL-6 and iNOS. Recently, gene silencing by DNA
methylation has been suggested to be associated also with methylation in regions up to 2 kb
from the islands (i.e., on the island edges), termed CpG island shores [49,50]. Future studies
are warranted to evaluate CpG shore methylation in children with asthma.
DNA methylation in the present study was limited to analyses on nasal cell DNA. We did
not collect additional tissues, such as, for example, buccal cells or blood, that have been
extensively used in studies on children and adults. Therefore, the correlation of nasal cell
DNA methylation with those DNA sources could not be explored in our study. Also, we
could not collect nasal cell samples using protocols that would have allowed for mRNA
expression studies.
Our study was designed to evaluate whether DNA methylation was associated with FENO,
FEV1 and wheezing within a group of children with asthma and did not include a group of
healthy controls. Therefore, we were unable to identify differences in DNA methylation that
are associated with asthma. Also, the present work did not consider potential effects from
nearby sources of exposures. The presence of a major petrochemical plant and an oil-
powered thermal plant in the area might have contributed to exacerbate asthmatic symptoms
in these children. The study group included children between 8–11 years of age, who were
Caucasians and predominantly males. The characteristics of the study participants limit the
generalizability of our findings to other age ranges and ethnical groups, as well as to the
female gender. In consideration of the small sample size we elected to report unadjusted
analyses, although we performed sensitivity analyses that confirmed the results of the study.
This is an additional limitation related to the small sample size of the study.
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Conclusion
This study provides proof of principle that DNA methylation in nasal cell DNA is related
with airway inflammation in a small group of children with current asthma. Whether our
findings can be extended to children with different degrees of asthma severity remains to be
determined. Our findings may establish a new model to obtain noninvasive measures of
epigenetic marks using nasal cell DNA, which might prove useful for research and clinical
purposes. Future studies are warranted to evaluate the determinants of DNA methylation
changes that are associated with asthma inflammation and severity, as well as to further
explore the role of DNA methylation in the natural history of asthma.
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Executive summary
• DNA methylation is increasingly being proposed as a mechanism for underlying
asthma-related inflammation.
• Whether altered DNA methylation contributes to airway inflammation and
obstruction in humans is largely unexplored.
• In this work, we tested the use of DNA from nasal cells obtained noninvasevely
through nasal brushing in 8–11 year old children with asthma.
• We measured DNA methylation of candidate biomarkers using highly
quantitative bisulfite-PCR-pyrosequencing.
• Levels of exhaled nitric oxide, a measure of lower-airway inflammation,
increased in association with lower promoter methylation of IL-6 and iNOS in
nasal cell DNA.
• Lower IL-6 methylation in nasal cell DNA was nonsignificantly associated with
wheezing during the week of the study.
• Alu and LINE-1 methylation levels were not associated with any of the
outcomes.
• Our findings support the use of nasal cell DNA for human epigenetic studies of
asthma.
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Figure 1. Correlation among DNA methylation of IL-6 and iNOS promoters, and in Alu and
LINE-1 repetitive elements (n = 62)
Significant correlations were found between LINE-1 and Alu methylation (r = 0.37; p =
0.003), LINE-1 and IL-6 methylation (r = −0.29; p = 0.02), and LINE-1 and iNOS
methylation (r = 0.36; p = 0.004).
LINE: Long interspersed nucleotide element.
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Table 2
Characteristics of study participants.
Characteristics n (%)
Age, year (mean ± standard deviation) 8.9 ± 0.8
Male 27 (77)
Parental schooling:
– University 8 (23)
– High school (13 year) 22 (63)
– <13 year 5 (14)
Maternal tobacco smoke exposure 8 (23)
Paternal tobacco smoke exposure 11 (31)
Damp or mould in child’s bedroom 5 (14)
Traffic intensity on street of residence (high) 3 (9)
Rhino conjunctivitis symptoms (past 12 months) 12 (34)
Chest tightness (past 12 months) 16 (48)
Prescription of bronchodilators (past 12 months) 22 (63)
Chest tightness in the study week 6 (17)
Respiratory infections in the study week and in the previous week 7 (20)
Bronchodilators in the study week 10 (29)
Antileukotrienes in the study week 6 (17)
Inhaled steroids in the study week 2 (6)
Antihistamines in the study week 5 (14)
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Table 3
Fractional exhaled nitric oxide, forced expiratory volume in 1 s and levels of DNA methylation of the IL-6 and
iNOS promoters and Alu and long interspersed nucleotide element 1 repetitive elements.
Variable (ppb) Mean SD IQR
FENO 36.30 29.80 36.00
FEV1(l) 2.17 0.47 0.68
IL-6 (%5mC) 51.40 12.00 16.10
iNOS (%5mC) 63.00 8.40 9.40
Alu (%5mC) 23.30 0.90 0.90
LINE-1 (%5mC) 72.30 4.10 4.90
%5mC: Percentage of 5-methyl-cytosine; FENO: Fractional exhaled nitric oxide; FEV1: Forced expiratory volume in 1 s; IQR: Interquartile range;
ppb: Parts per billion; SD: Standard deviation.
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